What is Survodutide?Overview
Survodutide is an investigational dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim (in partnership with Zealand Pharma) for the treatment of obesity, type 2 diabetes, and MASH (metabolic dysfunction-associated steatohepatitis). In Phase 2 trials, survodutide demonstrated up to 18.7% mean weight loss at 46 weeks—with 40% of patients achieving at least 20% weight loss.[1]
What makes survodutide unique is its dual glucagon/GLP-1 mechanism. Unlike tirzepatide (Zepbound), which activates GLP-1 and GIP receptors, survodutide activates GLP-1 and glucagon receptors. This may provide benefits beyond appetite suppression—potentially increasing energy expenditure and directly improving liver fat metabolism, making it particularly promising for patients with fatty liver disease.
- What It Is: Once-weekly subcutaneous injectable GLP-1/glucagon dual receptor agonist. First-in-class mechanism different from tirzepatide (GLP-1/GIP). Currently in Phase 3 trials.
- Efficacy Data: Phase 2 obesity trial: 18.7% weight loss at 46 weeks (completers). 40% achieved ≥20% weight loss. Weight loss had not plateaued—suggesting potential for greater loss with longer treatment.[1]
- Development Status: Phase 3 SYNCHRONIZE-1 and -2 trials fully enrolled (1,481 patients). Results expected H1 2026. FDA Breakthrough Therapy designation for MASH. Approval estimated 2027.[3]
Phase 2 results and SYNCHRONIZE Phase 3 program details
FDA Status & TimelinePhase 3 ongoing, FDA approval estimated 2027
Insurance Coverage GuidePost-approval coverage predictions and access strategies
Side Effects & SafetyGI side effects (nausea 56%), tolerability, and management
Why Survodutide Matters: Survodutide's glucagon component may offer advantages over pure GLP-1 or GLP-1/GIP agonists. Glucagon receptor activation can increase hepatic energy expenditure and fat oxidation—potentially making survodutide especially effective for patients with obesity-related liver disease (MASH/NASH). Phase 2 MASH data published in NEJM showed up to 62% of patients achieved MASH resolution without worsening fibrosis (vs. 14% placebo).[4]
For patients seeking alternatives to current medications, survodutide represents a pipeline option with a differentiated mechanism—though it won't be available until 2027 at the earliest.
How Survodutide WorksDual-Agonist Mechanism
Survodutide works by simultaneously activating two key metabolic hormone receptors: GLP-1 (glucagon-like peptide-1) and glucagon. This dual-agonist approach targets complementary pathways—reducing food intake while potentially increasing energy expenditure.[2]
GLP-1 Receptor Activation
The GLP-1 component of survodutide mimics the gut hormone GLP-1, which is naturally released after eating:
- Appetite Suppression: Activates GLP-1 receptors in the hypothalamus to reduce hunger and increase satiety between meals.
- Gastric Slowing: Delays gastric emptying, prolonging feelings of fullness after eating and reducing meal sizes.
- Glucose Control: Stimulates insulin secretion when blood sugar is elevated and suppresses inappropriate glucagon release.
Glucagon Receptor Activation
The glucagon component adds metabolic effects beyond GLP-1 alone—and this is what differentiates survodutide from other obesity drugs:
- Increased Energy Expenditure: Glucagon receptor activation in the liver may increase hepatic energy expenditure and thermogenesis—helping burn more calories.
- Liver Fat Reduction: Glucagon promotes fat oxidation in the liver, which may explain survodutide's remarkable efficacy in MASH (fatty liver disease).
- Lipid Metabolism: May improve cholesterol and triglyceride levels by enhancing hepatic lipid processing.
Different from Tirzepatide (Zepbound)
Tirzepatide (Zepbound/Mounjaro) activates GLP-1 and GIP receptors. Survodutide activates GLP-1 and glucagon receptors. The glucagon component's effect on energy expenditure and liver fat is what makes survodutide's mechanism unique—and may make it particularly suited for patients with MASH or metabolic syndrome.
Both are dual agonists, but they target different receptor pairs:
- Survodutide: GLP-1 + glucagon receptors (may increase energy expenditure)
- Tirzepatide: GLP-1 + GIP receptors (enhances insulin response)
Survodutide's glucagon component may make it more effective for liver fat reduction and MASH treatment. However, head-to-head clinical trials have not been conducted, so direct efficacy comparisons are limited.
Preclinical data and the drug's mechanism suggest yes. Glucagon receptor activation is known to increase hepatic energy expenditure and thermogenesis. As Carel le Roux (trial investigator) noted: "By activating both the glucagon and GLP-1 receptors, survodutide may both inhibit appetite and improve energy expenditure." However, direct measurement of energy expenditure changes in humans hasn't been extensively published.
Clinical EvidenceTrial Results
Survodutide's development has progressed through Phase 1 and Phase 2 trials with consistently positive results across obesity, type 2 diabetes, and MASH indications.
Phase 2 Obesity Trial (46 weeks)
Design: Randomized, double-blind, placebo-controlled, dose-finding trial in 386 adults with overweight/obesity (BMI ≥27) without type 2 diabetes. 20-week dose escalation + 26-week maintenance.[1]
Results (Week 46):
- 4.8mg dose (all randomized): -14.9% mean weight loss
- 4.8mg dose (completers): -18.7% mean weight loss
- Placebo: -2.8% mean weight loss
- ≥20% weight loss: 40% of patients on highest doses (vs. 0% placebo)
- ≥15% weight loss: 67% of patients (vs. 4.3% placebo)
Key Finding: Weight loss had not plateaued at week 46, suggesting additional weight loss could be achieved with longer treatment duration. This is being evaluated in the 76-week Phase 3 trials.
Phase 2 MASH Trial (48 weeks, NEJM 2024)
Design: 293 adults with biopsy-confirmed MASH and fibrosis (stages F1-F3). Published in the New England Journal of Medicine.[4]
Results (NEJM 2024):
- MASH resolution (no worsening fibrosis): 47% (2.4mg), 62% (4.8mg), 43% (6.0mg) vs. 14% placebo
- Best result: 62% at 4.8mg dose—highest efficacy observed
- ≥1 stage fibrosis improvement: 34-36% vs. 22% placebo
- Liver fat reduction ≥30%: 57-67% vs. 14% placebo
Phase 3 SYNCHRONIZE Program (Ongoing)
Boehringer Ingelheim initiated the Phase 3 SYNCHRONIZE program to support FDA approval:[3]
- SYNCHRONIZE-1 (Obesity without T2D): 726 patients, 76 weeks, enrollment complete
- SYNCHRONIZE-2 (Obesity with T2D): 755 patients, 76 weeks, enrollment complete June 2024
- SYNCHRONIZE-CVOT: Long-term cardiovascular outcomes trial (ongoing)
The 46-week duration was designed for dose-finding before investing in longer Phase 3 trials. Importantly, weight loss had not plateaued at 46 weeks—the curves were still trending downward. The Phase 3 SYNCHRONIZE trials are 76 weeks, which will show longer-term efficacy.
Direct comparison is difficult due to different trial designs, but here's context:
- Survodutide: 18.7% at 46 weeks (completers)
- Tirzepatide (SURMOUNT-1): 20.9% at 72 weeks
- Semaglutide (STEP 1): 14.9% at 68 weeks
Given that survodutide's weight loss hadn't plateaued at 46 weeks, the 76-week Phase 3 results may show comparable or higher final efficacy.
Safety and Side EffectsSafety Profile
Survodutide's safety profile in Phase 2 trials was consistent with the GLP-1 agonist class, featuring predominantly gastrointestinal adverse events that were most common during the rapid dose-escalation phase.[1]
Common Side Effects (Phase 2 Obesity)
- Nausea: 56% of patients
- Vomiting: 27% of patients
- Diarrhea: 22% of patients
- Constipation: 21% of patients
Tolerability Considerations
- Discontinuation Rate: 24.6% (survodutide) vs. 3.9% (placebo)—higher than some competitors
- Timing: Most discontinuations occurred during rapid dose-escalation phase (first 20 weeks)
- Serious Adverse Events: 4.2% (survodutide) vs. 6.5% (placebo)—lower than placebo
- Phase 3 Approach: Extended dose escalation may reduce GI side effects
Dose Escalation Matters
The Phase 2 trial used a rapid 20-week dose escalation, which likely contributed to higher GI side effects and discontinuation rates. The Phase 3 SYNCHRONIZE trials use an extended, flexible dose-escalation scheme that may significantly improve tolerability. Final safety data from Phase 3 will be more representative of real-world use.
Based on Phase 2 data, survodutide shows higher GI side effect rates than tirzepatide:
- Survodutide: Nausea 56%, discontinuation 24.6%
- Tirzepatide (SURMOUNT-1): Nausea 24-33%, discontinuation 4-7%
However, the rapid dose escalation in survodutide's Phase 2 likely inflated these numbers. Phase 3 trials with slower escalation should provide better comparison.
Path to FDA ApprovalApproval Timeline
Current Status: Phase 3 SYNCHRONIZE-1 and -2 enrollment completed. The 76-week treatment period means results are expected in H1 2026, with FDA filing to follow.
Regulatory Advantages: Survodutide has received FDA Breakthrough Therapy designation for MASH (Sept 2024), FDA Fast Track designation for NASH, and EMA PRIME designation. These may expedite the review process.
See complete FDA timeline and regulatory statusCurrent AccessClinical Trials
Survodutide is not yet FDA-approved and is only accessible through clinical trial participation. Multiple trials are ongoing:
- Visit ClinicalTrials.gov – Search "survodutide" or "BI 456906"
- SYNCHRONIZE-1/2: Enrollment completed (obesity trials)
- SYNCHRONIZE-CVOT: Cardiovascular outcomes trial may be enrolling
- LIVERAGE: MASH trials initiated Oct 2024, may be enrolling
- Benefits: Free medication, free medical monitoring, early access
Note: Boehringer Ingelheim is a large pharmaceutical company with extensive trial infrastructure. Trial sites are available in multiple countries across North America, Europe, and Asia.
See detailed trial information and enrollment criteriaInsurance Coverage OutlookCoverage Outlook
Survodutide is not yet FDA-approved and therefore not covered by any insurance plans. Post-approval coverage will depend on FDA labeling, pricing strategy, and payer negotiations.
Key Coverage Considerations
- Competitive Landscape: Survodutide will enter a market with established competitors (Zepbound, Wegovy). Differentiation on MASH/liver benefits may influence coverage.
- Boehringer's Position: As a major pharmaceutical company, Boehringer has established payer relationships and negotiating power.
- MASH Indication: If approved for MASH, survodutide could access a different coverage pathway for patients with liver disease.
- Type 2 Diabetes: If approved for T2D, Medicare Part D coverage becomes possible.
FAQs
Survodutide is expected to be available in 2027 if Phase 3 trials succeed. The SYNCHRONIZE trials (76 weeks) with enrollment completed means results will be available in H1 2026. FDA filing and review would follow, with potential approval in 2027.
Until then, access is limited to clinical trial participation.
No pricing has been announced. Based on the competitive landscape, analysts expect survodutide to be priced similarly to tirzepatide (Zepbound, ~$1,060/month) and semaglutide (Wegovy, ~$1,349/month), likely in the $1,000-1,400/month range.
Boehringer's pricing strategy will depend on Phase 3 efficacy results and the competitive landscape at launch.
Phase 2 data published in NEJM (2024) suggests survodutide may be particularly effective for MASH:
- MASH resolution: 47-62% vs. 14% placebo (62% at optimal 4.8mg dose)
- Fibrosis improvement: 34-36% vs. 22% placebo
- Liver fat reduction: 57-67% achieved ≥30% reduction
Survodutide has FDA Breakthrough Therapy designation for MASH. Phase 3 MASH trials (LIVERAGE) are ongoing.
Not recommended. Survodutide activates GLP-1 receptors (like Wegovy and Zepbound). Combining with another GLP-1-based medication could cause excessive GI side effects and unknown safety risks.
If survodutide is approved and you want to switch, work with your physician to safely transition off your current medication before starting survodutide.
Survodutide may offer advantages worth monitoring:
- Different mechanism: Glucagon activation may increase energy expenditure
- Liver benefits: Strong MASH data suggests particular benefit for patients with fatty liver
- Competition lowers prices: More options in the market could drive down costs
- Alternative if current meds don't work: Not all patients respond equally to all medications
However, survodutide won't be available until 2027. For patients who need treatment now, FDA-approved options like Zepbound and Wegovy remain the practical choices.
References
- le Roux CW, et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 2024;12(3):162-173. https://pubmed.ncbi.nlm.nih.gov/38330987/
- Boehringer Ingelheim / Zealand Pharma. Data shows nearly 19% weight loss in Phase II trial with survodutide. June 2023. https://www.globenewswire.com/news-release/2023/06/23/2693928
- Wharton S, et al. Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE-1 and -2). Obesity. 2025;33(1):44-54. https://pubmed.ncbi.nlm.nih.gov/39495965/
- Sanyal AJ, et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med. 2024;391:311-319. https://pubmed.ncbi.nlm.nih.gov/38847460/
- Boehringer Ingelheim. Boehringer Ingelheim to advance survodutide into three global Phase III studies in obesity. August 2023. https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/obesity/survodutide-phase-iii-study-weight-loss
- Zealand Pharma. Survodutide Pipeline. https://www.zealandpharma.com/pipeline/survodutide/
Last updated October 6, 2026
Disclaimer
The information on this page is for educational and informational purposes only and is not intended as medical advice. Honest Care does not provide medical diagnosis, treatment, or individualized recommendations. Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment.
While this content has been reviewed for accuracy and balance, new evidence may emerge after publication. Drug availability, indications, and insurance coverage can change over time. Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.